Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 6/20 | 0.41 |
| ▸ | GLP1R | P43220 | 1/20 | 0.40 |
| ▸ | GCGR | P47871 | 1/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | CASR | P41180 | 7/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3169132 | 0.80 | EPHX2 (0.40) | EPHX2GLP1RGCGRPTGDR2CYP2C9 | |
| SCHEMBL3166382 | 0.78 | PTGDR2 (0.39) | EPHX2GLP1RGCGRPTGDR2CYP2C9 | |
| SCHEMBL4272168 | 0.78 | EPHX2 (0.37) | EPHX2CYP2C9CYP2C19 | |
| SCHEMBL3168994 | 0.77 | HDAC1 (0.47) | EPHX2GLP1RGCGRPTGDR2CASR | |
| SCHEMBL4425058 | 0.75 | CASR (0.37) | EPHX2GLP1RGCGRPTGDR2CASR | |
| SCHEMBL3159511 | 0.75 | EPHX2 (0.51) | EPHX2GLP1RGCGRPTGDR2CYP2C9 | |
| SCHEMBL3173586 | 0.75 | MEN1 (0.49) | EPHX2 | |
| SCHEMBL12678723 | 0.73 | CASR (0.36) | EPHX2GLP1RGCGRPTGDR2CASR | |
| SCHEMBL12678724 | 0.73 | CASR (0.43) | EPHX2GLP1RGCGRPTGDR2CASR | |
| SCHEMBL3164868 | 0.72 | PTGDR2 (0.40) | EPHX2GLP1RGCGRPTGDR2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8273745-B2 | Polycyclic acid compounds useful as CRTH2 antagonists and antiallergic agents | ASTELLAS PHARMA INC (JP) | 2012-09-25 | — | — | US | disclosed |
| EP-2094662-B1 | POLYCYCLIC ACID COMPOUNDS USEFUL AS CRTH2 ANTAGONISTS AND ANTIALLERGIC AGENTS | ASTELLAS PHARMA INC (JP) | 2012-04-11 | — | — | EP | disclosed |
| US-20100009991-A1 | POLYCYCLIC ACID COMPOUNDS USEFUL AS CRTH2 ANTAGONISTS AND ANTIALLERGIC AGENTS | ASTELLAS PHARMA INC. (JP) | 2010-01-14 | — | — | US | disclosed |
| EP-2094662-A1 | POLYCYCLIC ACID COMPOUNDS USEFUL AS CRTH2 ANTAGONISTS AND ANTIALLERGIC AGENTS | Astellas Pharma Inc. (JP) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008072784-A1 | POLYCYCLIC ACID COMPOUNDS USEFUL AS CRTH2 ANTAGONISTS AND ANTIALLERGIC AGENTS | ASTELLAS PHARMA INC. (JP) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009991-A1 | POLYCYCLIC ACID COMPOUNDS USEFUL AS CRTH2 ANTAGONISTS AND ANTIALLERGIC AGENTS | HRH2, HRH1, HRH4 | EPHX2 2100/4885GLP1R 1377/4885GCGR 539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.